Thrombin activatable fibrinolysis inhibitor in Behcet's disease
Articles > Article · 2005
Authors: A Donmez, Kenan AKSU, Handan AK, Gökhan KESER, S Cagirgan, SB Omay, V Inal, Hikmet Hakan AYDIN, M Tombuloglu, E Doganavsargil
THROMBOSIS RESEARCH, Journal Indexed in SCI Expanded, International, 2005, vol 115, pp 287-292
DOI: 10.1016/j.thromres.2004.09.010
Summary
Introduction: Thrombin activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase downregulating plasmin formation, thereby causing a tendency for thrombosis development. Since, Behcet's disease (BD) is a systemic vasculitis, which is commonly complicated by arterial and venous thrombosis, we aimed to find out plasma TAR levels in BD, compared with healthy controls. We also searched whether plasma TAFI levels were significantly different between Behcet's subgroups with and without thrombosis.